Belete Rebuma, Ataro Zerihun, Abdu Ahmedmenewer, Sheleme Merga
Department of Medical Laboratory Sciences, College of Health and Medical Sciences, Haramaya University, Harar, Ethiopia.
School of Medicine, College of Health and Medical Sciences, Haramaya University, Harar, Ethiopia.
Diabetol Metab Syndr. 2021 Mar 2;13(1):25. doi: 10.1186/s13098-021-00641-8.
The presence of metabolic syndrome among diabetes patients is frequent and is associated with an increased incidence of chronic complications and mortality. Despite several studies have been conducted, there is no overall estimation on the prevalence of metabolic syndrome among type 1 diabetic patients. Therefore, this study aimed to estimate the pooled prevalence of metabolic syndrome among patients with type 1 diabetes mellitus.
Medline via PubMed, CINAHL, ScienceDirect, Ovid, Google Scholar, ResearchGate and African Journals Online were searched by limiting publication period from January 2005 to October 2020. Data were extracted with a standardized format prepared in Microsoft Excel and exported to Stata 16.0 for analyses. The I statistic was used to check heterogeneity across the included studies. DerSimonian and Laird random-effects model was applied to estimate pooled prevalence and 95% confidence interval across studies. Funnel plot symmetry, Begg's test and Egger's regression test were used to determine the presence of publication bias. Subgroup and sensitivity analysis as well as meta-regression were conducted to explore the potential sources of heterogeneity. The study protocol is registered on PROSPERO with reference number: CRD42020213435.
In this meta-analysis, a total of 27 studies with 45,811 study participants were included. The pooled prevalence of metabolic syndrome was 23.7% with substantial heterogeneity (I = 98.2%; P < 0.001). Geographical-based subgroup analysis revealed that the highest prevalence was observed in Australia (27.3%). As per meta-analysis of 17 studies, the pooled prevalence of metabolic syndrome in female type 1 diabetes patients (25.9%) was slightly higher than male T1DM patients (22.5%).
Nearly a quarter of the type 1 diabetes mellitus patients were affected by metabolic syndrome. Therefore, more attention should be paid to the prevention and control of the epidemic and for the reduction of the morbidity and mortality associated with metabolic syndrome among type 1 diabetes mellitus patients.
糖尿病患者中代谢综合征的情况很常见，且与慢性并发症和死亡率的增加有关。尽管已经开展了多项研究，但对于1型糖尿病患者中代谢综合征的患病率尚无总体估计。因此，本研究旨在估计1型糖尿病患者中代谢综合征的合并患病率。
通过PubMed、CINAHL、ScienceDirect、Ovid、谷歌学术、ResearchGate和非洲期刊在线检索Medline，限定发表时间为2005年1月至2020年10月。数据采用在Microsoft Excel中准备的标准化格式提取，并导出到Stata 16.0进行分析。I统计量用于检验纳入研究之间的异质性。采用DerSimonian和Laird随机效应模型估计各研究的合并患病率和95%置信区间。采用漏斗图对称性、Begg检验和Egger回归检验来确定发表偏倚的存在。进行亚组和敏感性分析以及meta回归以探索异质性的潜在来源。该研究方案已在PROSPERO注册，注册号为：CRD42020213435。
在这项荟萃分析中，共纳入了27项研究，涉及45811名研究参与者。代谢综合征的合并患病率为23.7%，存在显著异质性（I = 98.2%；P < 0.001）。基于地理的亚组分析显示，澳大利亚的患病率最高（27.3%）。根据对17项研究的荟萃分析，1型糖尿病女性患者中代谢综合征的合并患病率（25.9%）略高于男性1型糖尿病患者（22.5%）。
近四分之一的1型糖尿病患者受代谢综合征影响。因此，应更加关注该流行病的预防和控制，以降低1型糖尿病患者中与代谢综合征相关的发病率和死亡率。
